Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 5Genitourinary 4Breast 4Sarcoma 3Gastrointestinal 3CNS 2Plasma cell 1Other solid neoplasm 1Other hematologic neoplasm 1Myeloid 1Head & Neck 1Gynecologic 1Dermatologic 1

Conditions

Melanoma 1Central Nervous System Neoplasms 1Brain Neoplasms 1

Interventions

Ipilimumab 101pembrolizumab 94Nivolumab 87Cyclophosphamide 69fludarabine phosphate 55aldesleukin 52Interleukin-2 39Dacarbazine 35Vemurafenib 31fludarabine 30trametinib 29dabrafenib 29Temozolomide 28Whole-Body Irradiation 21Aminolevulinic Acid 21Carboplatin 20CTLA-4 Antigen 20Bevacizumab 20Radiotherapy 19Peripheral Blood Stem Cell Transplantation 19Radiosurgery 18Tacrolimus 17Mycophenolic Acid 17Paclitaxel 16HhAntag691 163-ingenyl angelate 16Busulfan 15Introns 14Antilymphocyte Serum 14encorafenib 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Immunoenzyme Techniques × Dermatologic × Clear all
NCT00512798 2012-10-02

Bortezomib and Temozolomide in Treating Patients With Advanced Refractory Solid Tumors or Melanoma

Vanderbilt-Ingram Cancer Center

Phase 1/2 Terminated
47 enrolled 9 charts
CNSDermatologic

Brain Neoplasms, Melanoma, Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡